Ultragenyx agrees to sell priority review voucher for $203 million
Ultragenyx entered into an agreement to sell a Rare Pediatric Disease Priority Review Voucher for $203 million.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.